Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-DENV-2 Envelope protein E/EDIII (Iv0124)

Catalog #:   VVV19901 Specific References (24) DATASHEET
Host species: Human
Isotype: IgG1
Applications: ELISA, Neutralization
Accession: W5RZ25,P18356
Overview

Catalog No.

VVV19901

Species reactivity

Dengue virus type 2 (DENV-2)

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Applications

ELISA, Neutralization

Target

E glycoprotein, Envelope protein E, EDIII

Concentration

2.43 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

W5RZ25,P18356

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0124

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image
References

Infectious clone construction of dengue virus type 2, strain Jamaican 1409, and characterization of a conditional E6 mutation., PMID:16847122

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes., PMID:17881453

Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines., PMID:18160621

Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia., PMID:20651932

Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses., PMID:21419774

Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli., PMID:22420529

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection., PMID:23545366

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection., PMID:23785205

Dengue virus type 2: protein binding and active replication in human central nervous system cells., PMID:24302878

Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing., PMID:24335303

Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention., PMID:24550728

Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees., PMID:26889737

In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2., PMID:28400226

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852

Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection., PMID:31636070

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868

Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo., PMID:32517029

Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo., PMID:33299049

Sulfated β-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis., PMID:35533778

Quercetin attenuates viral infections by interacting with target proteins and linked genes in chemicobiological models., PMID:36119653

N-Butanol Extract of Glycyrrhizae Radix et Rhizoma Inhibits Dengue Virus through Targeting Envelope Protein., PMID:37259408

Liang-Ge-San inhibits dengue virus serotype 2 infection by reducing caveolin1-induced cytoplasmic heat shock protein 70 translocation into the plasma membrane., PMID:37506573

Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis., PMID:39085250

Darunavir inhibits dengue virus replication by targeting the hydrophobic pocket of the envelope protein., PMID:40024350

Datasheet
$ 350
Product specifications
100 μg 350 1 mg 1400 5 mg 4200

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-DENV-2 Envelope protein E/EDIII (Iv0124) [VVV19901]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only